Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 329 clinical trials
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear

  • 07 Mar, 2021
  • 74 locations
Avelumab/Gemcitabine in Sarcomatoid RCC

To determine the feasibility and safety of avelumab and gemcitabine combination therapy in patients with metastatic sRCC.

  • 03 Feb, 2021
  • 1 location
Immunochemotherapy for Metastatic Renal Cell Carcinoma

Immunochemotherapy consisting of IL-2, INF-A, and VBL and 5FU is regarded as the treatment of choice in metastatic renal cell carcinoma. During the period 1996-2000, we evaluated the

  • 07 Nov, 2020
  • 1 location
Molecular Determinants for Therapy Response on Renal Cell Carcinoma

Aim of the scientific analysis is to find biological factors (biomarkers) allowing a prediction of disease progression and a better choice of therapy. After diagnosis the kidney and the tumor will be removed by standard surgery followed by drug therapy. Within surgery remaining tumor tissue will be used for the …

kidney cancer
systemic therapy
  • 08 Nov, 2020
Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

The objective of the trial is to determine the clinical efficacy of ESK981 in combination with nivolumab therapy in patients with metastatic renal cell carcinoma.

vascular endothelial growth factor
measurable disease
karnofsky performance status
  • 26 Jan, 2021
  • 1 location
A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

and metastatic renal cell carcinoma. This study consists of two parts: Dose Escalation and Dose Expansion. During the dose escalation phase, participants will be sequentially enrolled in a standard 3

  • 27 Jan, 2021
  • 1 location
Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma

metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.

  • 29 Jan, 2021
  • 1 location
Ketogenic Diet for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma

The purpose of this study is to evaluate the tolerance of one year of ketogenic diet associated with vitamin supplementation in patients treated for a metastatic renal cell carcinoma.

  • 26 Jan, 2021
  • 1 location
Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

in vitro transcribed (IVT) RNA from an autologous tumor specimen and CD40L RNA. CMN-001 is indicated for treatment of intermediate/poor risk patients with advanced renal cell carcinoma (RCC) in

  • 26 Jan, 2021
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

This study aims to test if patients achieving a tumor response with the combination of axitinib plus avelumab, can discontinued the axitinib in order to delay the resistance to the anti VEGFR-TKI and decrease the related toxicity of the combination therapy.

  • 27 Jan, 2021
  • 20 locations